AGREEMENT AND PLAN OF
MERGER
KIMBERLY-CLARK
CORPORATION,
Dated as of October 8,
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
Section 1.2 Offer Documents
|
|
|
3
|
|
Section 1.3 Company Actions
|
|
|
4
|
|
|
|
|
|
5
|
|
Section 1.5 The Top-Up Option
|
|
|
6
|
|
Section 1.6
Short-Form Merger
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
8
|
|
Section 2.3 Effective Time
|
|
|
8
|
|
Section 2.4 Effects of the
Merger
|
|
|
8
|
|
Section 2.5 Certificate of Incorporation;
Bylaws
|
|
|
8
|
|
|
|
|
|
9
|
|
|
|
|
|
9
|
|
|
|
|
|
|
|
ARTICLE III EFFECT ON THE CAPITAL STOCK OF THE
CONSTITUENT CORPORATIONS; EXCHANGE OF CERTIFICATES
|
|
|
9
|
|
|
|
|
|
|
|
Section 3.1 Conversion of Capital
Stock
|
|
|
9
|
|
Section 3.2 Treatment of Options,
Restricted Stock Units and Restricted Stock
|
|
|
9
|
|
Section 3.3 Exchange and Payment
|
|
|
10
|
|
Section 3.4 Withholding Rights
|
|
|
12
|
|
Section 3.5 Dissenting Shares
|
|
|
13
|
|
|
|
|
|
|
|
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE
COMPANY
|
|
|
13
|
|
|
|
|
|
|
|
Section 4.1 Organization, Standing and
Power
|
|
|
14
|
|
Section 4.2 Capital Stock
|
|
|
15
|
|
|
|
|
|
17
|
|
Section 4.4 No Conflict; Consents and
Approvals
|
|
|
18
|
|
Section 4.5 SEC Reports; Financial
Statements
|
|
|
19
|
|
Section 4.6 No Undisclosed
Liabilities
|
|
|
20
|
|
Section 4.7 Certain Information
|
|
|
21
|
|
Section 4.8 Absence of Certain Changes or
Events
|
|
|
21
|
|
|
|
|
|
21
|
|
Section 4.10 Compliance with
Laws
|
|
|
22
|
|
Section 4.11 Benefit Plans
|
|
|
24
|
|
Section 4.12 Labor Matters
|
|
|
26
|
|
i
TABLE OF CONTENTS
(Continued)
|
|
|
|
|
|
|
|
|
|
Section 4.13 Environmental
Matters
|
|
|
27
|
|
|
|
|
|
27
|
|
|
|
|
|
29
|
|
|
|
|
|
30
|
|
|
|
|
|
30
|
|
Section 4.18 Intellectual
Property
|
|
|
31
|
|
|
|
|
|
32
|
|
|
|
|
|
32
|
|
Section 4.21 Takeover Statutes
|
|
|
32
|
|
Section 4.22 Fairness Opinion
|
|
|
33
|
|
Section 4.23 Affiliate
Transactions
|
|
|
33
|
|
Section 4.24 Exclusivity of Representations
and Warranties
|
|
|
33
|
|
|
|
|
|
|
|
ARTICLE V REPRESENTATIONS AND WARRANTIES OF
PARENT AND MERGER SUB
|
|
|
33
|
|
|
|
|
|
|
|
Section 5.1 Organization, Standing and
Power
|
|
|
34
|
|
|
|
|
|
34
|
|
Section 5.3 No Conflict; Consents and
Approvals
|
|
|
35
|
|
Section 5.4 Certain Information
|
|
|
35
|
|
|
|
|
|
36
|
|
Section 5.6 Ownership and Operations of
Merger Sub
|
|
|
36
|
|
|
|
|
|
36
|
|
Section 5.8 Vote/Approval
Required
|
|
|
36
|
|
|
|
|
|
37
|
|
Section 5.10 Interested
Stockholder
|
|
|
37
|
|
Section 5.11 No Other Representations or
Warranties
|
|
|
37
|
|
Section 5.12 Ownership of Shares
|
|
|
37
|
|
|
|
|
|
|
|
|
|
|
|
37
|
|
|
|
|
|
|
|
Section 6.1 Conduct of Business of the
Company
|
|
|
37
|
|
Section 6.2 No Control of Other
Party’s Business
|
|
|
40
|
|
Section 6.3 Acquisition
Proposals
|
|
|
40
|
|
Section 6.4 Preparation of Proxy Statement;
Stockholders Meeting
|
|
|
44
|
|
Section 6.5 Access to Information;
Confidentiality
|
|
|
45
|
|
Section 6.6 Further Action;
Efforts
|
|
|
45
|
|
Section 6.7 Employment and Employee
Benefits Matters; Other Plans
|
|
|
47
|
|
Section 6.8 Notification of Certain
Matters
|
|
|
49
|
|
Section 6.9 Indemnification, Exculpation
and Insurance
|
|
|
49
|
|
|
|
|
|
51
|
|
Section 6.11 Anti-Takeover
Statute
|
|
|
51
|
|
ii
TABLE OF CONTENTS
(Continued)
|
|
|
|
|
|
|
|
|
|
Section 6.12 Stockholder
Litigation
|
|
|
51
|
|
Section 6.13 Public
Announcements
|
|
|
51
|
|
Section 6.14 Rule 14d-10(d)
Matters
|
|
|
52
|
|
Section 6.15 Transfer Taxes
|
|
|
52
|
|
|
|
|
|
|
|
ARTICLE VII CONDITIONS PRECEDENT
|
|
|
52
|
|
|
|
|
|
|
|
Section 7.1 Conditions to Each
Party’s Obligations to Effect the Merger
|
|
|
52
|
|
|
|
|
|
|
|
ARTICLE VIII TERMINATION, AMENDMENT AND
WAIVER
|
|
|
53
|
|
|
|
|
|
|
|
|
|
|
|
53
|
|
Section 8.2 Effect of
Termination
|
|
|
54
|
|
Section 8.3 Fees and Expenses
|
|
|
55
|
|
Section 8.4 Amendment or
Supplement
|
|
|
56
|
|
Section 8.5 Extension of Time;
Waiver
|
|
|
57
|
|
|
|
|
|
|
|
ARTICLE IX GENERAL PROVISIONS
|
|
|
57
|
|
|
|
|
|
|
|
Section 9.1 Nonsurvival of Representations
and Warranties
|
|
|
57
|
|
|
|
|
|
57
|
|
Section 9.3 Certain Definitions
|
|
|
58
|
|
Section 9.4 Interpretation
|
|
|
59
|
|
Section 9.5 Entire Agreement
|
|
|
60
|
|
Section 9.6 Parties in Interest
|
|
|
60
|
|
Section 9.7 Governing Law
|
|
|
60
|
|
Section 9.8 Submission to
Jurisdiction
|
|
|
60
|
|
Section 9.9 Assignment;
Successors
|
|
|
61
|
|
|
|
|
|
61
|
|
|
|
|
|
61
|
|
Section 9.12 Severability
|
|
|
61
|
|
Section 9.13 Waiver of Jury
Trial
|
|
|
62
|
|
Section 9.14 Counterparts
|
|
|
62
|
|
Section 9.15 Electronic
Signature
|
|
|
62
|
|
Section 9.16 No Presumption Against
Drafting Party
|
|
|
62
|
|
Section 9.17 Disclosure Letters
|
|
|
62
|
|
Section 9.18 Obligations of Merger Sub and
Surviving Corporation
|
|
|
63
|
|
iii
|
|
|
|
|
Definition
|
|
Location
|
Acceptable Confidentiality Agreement
|
|
6.3(h)(i)
|
|
|
|
1.1(c)
|
|
|
|
4.1(a)
|
|
|
|
4.1(a)
|
|
|
|
8.3(c)(i),
6.3(h)(ii)
|
|
|
|
4.9
|
Adverse Recommendation Change
|
|
6.3(d)
|
|
|
|
9.3(a)
|
|
|
|
Preamble
|
Alternative Acquisition Agreement
|
|
6.3(d)
|
|
|
|
6.6(e)
|
|
|
|
6.7(d)
|
|
|
|
3.3(b)
|
|
|
|
9.3(b)
|
|
|
|
2.3
|
|
|
|
3.3(b)
|
|
|
|
2.2
|
|
|
|
2.2
|
|
|
|
3.4
|
|
|
|
Preamble
|
|
|
|
Recitals
|
Company Constituent Documents
|
|
4.1(b)
|
Company Disclosure Documents
|
|
4.7(a)
|
Company Disclosure Letter
|
|
Article
IV
|
|
|
|
6.7(a)
|
|
|
|
3.2(a)
|
|
|
|
4.11(a)
|
|
|
|
1.3(a)
|
|
|
|
4.18(a)
|
|
|
|
3.2(b)
|
|
|
|
4.5(a)
|
|
|
|
3.2(a)
|
Company Stockholder Approval
|
|
4.3
|
Company Stockholders Meeting
|
|
6.4(b)
|
Confidentiality Agreement
|
|
6.5(b)
|
|
|
|
4.15
|
|
|
|
9.3(c)
|
|
|
|
6.9(a)
|
|
|
|
6.7(d)
|
|
|
|
6.9(c)
|
|
|
|
1.1(b)
|
|
|
|
1.4(a)
|
iv
INDEX OF DEFINED TERMS
(Continued)
|
|
|
|
|
Definition
|
|
Location
|
|
|
|
3.5
|
|
|
|
4.10(f)
|
|
|
|
2.3
|
|
|
|
4.13(c)(i)
|
|
|
|
4.13(c)(ii)
|
|
|
|
4.11(a)
|
|
|
|
4.11(c)
|
|
|
|
1.1(a)
|
|
|
|
3.3(a)
|
|
|
|
3.3(a)
|
|
|
|
8.3(c)(ii)
|
|
|
|
4.10(d)
|
Federal Health Care Programs
|
|
4.10(f)
|
|
|
|
4.4(b)
|
|
|
|
6.6(b)
|
|
|
|
4.5(b)
|
|
|
|
4.4(b)
|
|
|
|
4.4(b)
|
|
|
|
6.9(a)
|
|
|
|
1.4(c)
|
|
|
|
4.18(a)
|
|
|
|
4.11(a)
|
|
|
|
9.3(d)
|
|
|
|
4.4(a)
|
|
|
|
4.2(a)
|
|
|
|
4.1(a)
|
|
|
|
4.15
|
Materials of Environmental Concern
|
|
4.13(c)(iii)
|
|
|
|
Recitals
|
|
|
|
Exhibit
A
|
|
|
|
3.1(a)
|
|
|
|
Preamble
|
|
|
|
Exhibit
A
|
Notice of Superior Proposal
|
|
6.3(f)
|
|
|
|
6.3(f)
|
|
|
|
Recitals
|
|
|
|
1.1(a)
|
|
|
|
1.2
|
|
|
|
3.1(a)
|
|
|
|
1.2
|
|
|
|
9.3(e)
|
|
|
|
Preamble
|
v
INDEX OF DEFINED TERMS
(Continued)
|
|
|
|
|
Definition
|
|
Location
|
|
|
|
Article
V
|
Parent Material Adverse Effect
|
|
5.1(a)
|
|
|
|
6.7(b)
|
|
|
|
4.10(b)
|
|
|
|
4.17(a)
|
|
|
|
9.3(f)
|
|
|
|
4.7(a)
|
|
|
|
4.17(b)
|
|
|
|
6.3(b)
|
|
|
|
Recitals
|
|
|
|
Recitals
|
|
|
|
1.3(b)
|
|
|
|
1.2
|
|
|
|
1.1(b)
|
|
|
|
1.5(d)
|
|
|
|
Recitals
|
|
|
|
4.5(d)
|
|
|
|
4.10(f)
|
Subsequent Offering Period
|
|
1.1(b)
|
|
|
|
9.3(g)
|
|
|
|
6.3(h)(iii)
|
|
|
|
Recitals
|
|
|
|
2.1
|
|
|
|
4.21
|
|
|
|
4.14(l)(ii)
|
|
|
|
4.14(l)(i)
|
|
|
|
Exhibit
A
|
|
|
|
8.3(c)(iii)
|
|
|
|
1.5(c)
|
|
|
|
1.5(a)
|
|
|
|
1.5(a)
|
Unvested Restricted Stock
|
|
3.2(c)
|
|
|
|
4.12
|
vi
AGREEMENT AND PLAN OF
MERGER
THIS AGREEMENT AND
PLAN OF MERGER (this “ Agreement ”), dated as of
October 8, 2009, is by and among KIMBERLY-CLARK CORPORATION, a
Delaware corporation (“ Parent ”), BOXER
ACQUISITION, INC., a Delaware corporation and a wholly owned
subsidiary of Parent (“ Merger Sub ”) and I-FLOW
CORPORATION, a Delaware corporation (the “ Company
”).
WHEREAS, it is
proposed that Merger Sub shall commence an offer to purchase all of
the outstanding shares of common stock, par value $0.001 per share,
of the Company (“ Shares ”), together with the
associated purchase rights (the “ Rights ”)
issued pursuant to the Rights Agreement, dated as of March 8,
2002, between the Company and American Stock Transfer & Trust
Company, a New York corporation, as Rights Agent (the “
Rights Agreement ”), for the Offer Price (as defined
in Section 3.1(a) hereof) (as may be amended from time
to time in accordance with this Agreement, the “ Offer
”), on the terms and subject to the conditions set forth
herein;
WHEREAS, it is
also proposed that, following the consummation of the Offer, Merger
Sub will be merged with and into the Company with the Company
surviving as a wholly owned Subsidiary (as defined in
Section 9.3(g) hereof) of Parent, on the terms and
subject to the conditions set forth herein (the “
Merger ”);
WHEREAS, the
Boards of Directors of Parent and Merger Sub have each approved
this Agreement and declared it advisable for Parent and Merger Sub,
respectively, to enter into this Agreement;
WHEREAS, the Board
of Directors of the Company (the “ Company Board
”) has, subject to the terms and conditions of this
Agreement, unanimously (i) determined that it is in the best
interests of the Company and its stockholders, and declared it
advisable, to enter into this Agreement, (ii) approved the
execution, delivery and performance by the Company of this
Agreement and the consummation of the transactions contemplated
hereby, including the Offer and the Merger and (iii) resolved
and agreed to recommend that the Company’s stockholders
accept the Offer, tender their Shares pursuant to the Offer and
adopt this Agreement;
WHEREAS, as an
inducement to and condition to Parent’s and Merger
Sub’s willingness to enter into this Agreement, certain
stockholders of the Company are entering into a Tender and Support
Agreement (each, a “ Support Agreement ”) with
Parent and Merger Sub simultaneously with the execution and
delivery of this Agreement; and
WHEREAS, Parent,
Merger Sub and the Company desire to make certain representations,
warranties, covenants and agreements in connection with the Offer
and the Merger and also to prescribe certain conditions to the
Offer and the Merger as specified herein.
NOW, THEREFORE, in
consideration of the premises, and of the representations,
warranties, covenants and agreements contained herein, and
intending to be legally bound hereby, Parent, Merger Sub and the
Company hereby agree as follows:
(a)
Provided that this Agreement shall not have been terminated
in accordance with Article VIII and subject to the
conditions set forth in this Agreement and Exhibit A hereto,
as promptly as reasonably practicable after the date hereof, and in
any event within seven (7) Business Days (as defined in
Section 9.3(b) hereof) after such date, Merger Sub
shall, and Parent shall cause Merger Sub to, commence (within the
meaning of Rule 14d-2 under the Securities Exchange Act of
1934, as amended (including the rules and regulations promulgated
thereunder, the “ Exchange Act ”)) the Offer.
The obligations of Merger Sub, and of Parent to cause Merger Sub,
to accept for payment and pay for any Shares tendered pursuant to
the Offer and not validly withdrawn pursuant to the Offer shall be
subject to the satisfaction or waiver by Merger Sub of the
conditions set forth in Exhibit A hereto and the terms
and conditions hereof (collectively, the “ Offer
Conditions ”). Merger Sub may, in its sole discretion,
waive any Offer Condition or modify the terms or conditions of the
Offer consistent with the terms of this Agreement, except that,
without the prior written consent of the Company, Merger Sub shall
not (i) reduce the Offer Price, (ii) change the form of
consideration payable in the Offer (other than by adding
consideration), (iii) reduce the number of Shares to be
purchased in the Offer, (iv) waive or change the Minimum Condition
or the Termination Condition (as such terms are defined in
Exhibit A ), (v) add to the Offer Conditions or
modify them in a manner adverse to the holders of Shares,
(vi) extend the expiration of the Offer except as required or
permitted by Section 1.1(b) or (vii) modify any
term of the Offer set forth in this Agreement in a manner adverse
to the holders of Shares.
(b) The
Offer shall initially expire at midnight, New York City time, on
the date that is twenty (20) business days (for purposes of
this Section 1.1(b) , business days shall be calculated
in accordance with Rule 14d-1(g)(3) under the Exchange Act)
after the commencement of the Offer, except as may otherwise be
required by applicable Law (as defined in Section 4.4(a)
hereof); provided , however , that if at any
scheduled expiration date of the Offer, the Offer Conditions shall
not have been satisfied or waived, and if this Agreement shall not
have been terminated in accordance with Article VIII ,
Merger Sub may (in its sole discretion, without consent of the
Company), and, to the extent requested in writing by the Company
prior to such scheduled expiration date, shall, extend the Offer
for one or (as needed) more additional consecutive periods of up to
twenty (20) business days per extension but at least ten
(10) business days per extension (with the length of such
periods within such range to be determined in the sole discretion
of Parent consistent with applicable Law); provided ,
further , that Merger Sub shall not be obligated to extend
the Offer past the Outside Date (as defined in
Section 9.3(e) hereof); provided ,
further , that if this Agreement shall not have been
terminated in accordance with Article VIII , Merger Sub
shall also extend the Offer for any additional period required
by
2
any rule,
regulation, interpretation or position of the Securities and
Exchange Commission (the “ SEC ”) or the staff
thereof or the rules of the Nasdaq Stock Market applicable to the
Offer; provided , further , that Merger Sub may,
until the Outside Date, in its sole discretion, provide one or more
subsequent offering periods (each, a “ Subsequent Offering
Period ”) after the expiration of the Offer, in
accordance with Rule 14d-11 under the Exchange Act, if, as of
the commencement of each such Subsequent Offering Period, there
shall not have been validly tendered and not withdrawn pursuant to
the Offer and any prior Subsequent Offering Period that number of
Shares necessary to permit the Merger to be effected without a
meeting of stockholders of the Company, in accordance with Section
253(a) of the General Corporation Law of the State of Delaware (the
“ DGCL ”).
(c) Subject
to the terms of the Offer and this Agreement and the satisfaction
of all of the Offer Conditions, Merger Sub shall accept for payment
and pay for all Shares validly tendered and not validly withdrawn
pursuant to the Offer as soon as practicable after the expiration
date thereof (as the same may be extended or required to be
extended) or (in the case of any Shares tendered during any
Subsequent Offering Period) as soon as practicable following the
valid tender thereof. For the avoidance of doubt, if, at any
scheduled expiration date of the Offer, all of the Offer Conditions
have been satisfied or waived and this Agreement has not otherwise
been terminated in accordance with its terms, Merger Sub shall on
such date accept for payment and pay for all Shares validly
tendered and not validly withdrawn pursuant to the Offer in
accordance with this Agreement (the time at which such acceptance
occurs on such date, the “ Acceptance Time ”).
For the further avoidance of doubt, the Acceptance Time shall not
be extended by any Subsequent Offering Period.
(d) In
the event this Agreement is terminated pursuant to
Article VIII prior to the acceptance of Shares tendered
pursuant to the Offer, Parent and Merger Sub shall promptly
terminate the Offer without accepting any Shares previously
tendered.
Section 1.2
Offer Documents . As promptly as reasonably practicable on
the date of commencement of the Offer, Parent and Merger Sub shall
(a) file a Tender Offer Statement on Schedule TO
(together with all amendments, supplements and exhibits thereto,
the “ Schedule TO ”) with respect to the
Offer, which shall contain or shall incorporate by reference an
offer to purchase (the “ Offer to Purchase ”)
and forms of the related letter of transmittal and form of summary
advertisement (the Schedule TO and the Offer to Purchase,
together with all amendments, supplements and exhibits thereto, the
“ Offer Documents ”) and (b) cause the
Offer Documents to be disseminated to the Company’s
stockholders, in each case as and to the extent required by the
Exchange Act. The Company shall promptly provide Parent and Merger
Sub in writing, for inclusion in the Offer Documents, all
information concerning the Company that is required under the
Exchange Act to be included in the Offer Documents. Each of Parent,
Merger Sub and the Company agrees promptly to correct any
information provided by it for use in the Offer Documents if and to
the extent that such information becomes false or misleading in any
material respect, and each of Parent and Merger Sub further agrees
to take all steps necessary to cause the Offer Documents as so
corrected to be filed with the SEC and to be disseminated to the
Company’s stockholders, in each case as and to the extent
required by the Exchange Act. The Company and its counsel shall be
given a reasonable opportunity to review and comment on the Offer
Documents and any amendments and supplements thereto prior to the
filing thereof with the SEC, and Parent shall give reasonable
consideration to all additions, deletions, changes and
3
other comments
suggested by the Company and its counsel. In addition, Parent and
Merger Sub shall provide to the Company and its counsel any
comments, whether written or oral, that Parent or Merger Sub may
receive from the SEC or its staff with respect to the Offer
Documents promptly after the receipt of such comments, and any
written or oral responses thereto. The Company and its counsel
shall be given a reasonable opportunity to review and comment upon
such responses and Parent shall give reasonable consideration to
all additions, deletions, changes or other comments suggested by
the Company and its counsel.
Section 1.3
Company Actions .
(a) Subject
to Section 6.3 , the Company hereby consents to the
Offer and, so long as no Adverse Recommendation Change (as defined
in Section 6.3(d) hereof) has occurred in accordance
with Section 6.3 , to the inclusion in the Offer
Documents of the recommendation of the Company Board recommending
that the holders of Shares accept the Offer, tender their Shares to
Merger Sub pursuant to the Offer and, if necessary under applicable
Law, adopt this Agreement and approve the Merger and the other
transactions contemplated hereby in accordance with the provisions
of the DGCL (the “ Company Recommendation
”).
(b) As
promptly as reasonably practicable on or after the date of filing
by Parent and Merger Sub of the Offer Documents, the Company shall
file with the SEC and disseminate to the Company’s
stockholders, in each case as and to the extent required by the
Exchange Act, a Solicitation/Recommendation Statement on
Schedule 14D-9 (such Solicitation/Recommendation Statement on
Schedule 14D-9, together with any amendments, supplements and
exhibits thereto, the “ Schedule 14D-9 ”)
containing the Company Recommendation (subject to
Section 6.3 ), and the Company shall cause the
Schedule 14D-9 to be disseminated to the Company’s
stockholders ( provided that Merger Sub shall use
commercially reasonable efforts to cause the Schedule 14D-9 to be
disseminated concurrently with and in the same mailing envelope as
the Offer Documents, if requested by the Company) as required by
Rule 14d-9 under the Exchange Act. Each of Parent and Merger
Sub shall, as promptly as practicable, furnish to the Company in
writing all information concerning Parent and Merger Sub that is
required by the Exchange Act to be included in the
Schedule 14D-9. Each of the Company, Parent and Merger Sub
agrees promptly to correct any information provided by it for use
in the Schedule 14D-9 if and to the extent that such
information becomes false or misleading in any material respect,
and the Company further agrees to take all steps necessary to cause
the Schedule 14D-9 as so corrected to be filed with the SEC
and to be disseminated to the Company’s stockholders, in each
case, as and to the extent required by applicable Law. Parent,
Merger Sub and their counsel shall be given a reasonable
opportunity to review and comment on the Schedule 14D-9 and
any amendments and supplements thereto prior to the filing thereof
with the SEC and the Company shall give reasonable consideration to
all additions, deletions, changes or other comments suggested by
Parent, Merger Sub and their counsel. In addition, the Company
agrees to provide Parent, Merger Sub and their counsel any
comments, whether written or oral, that the Company or its counsel
may receive from the SEC or its staff with respect to the
Schedule 14D-9 promptly after the receipt of such comments,
and any written or oral responses thereto. Parent, Merger Sub and
their counsel shall be given a reasonable opportunity to review and
comment upon such responses, and the Company shall give reasonable
consideration to all additions, deletions, changes or other
comments suggested by Parent, Merger Sub and their
counsel.
4
(c) In
connection with the Offer, the Company shall request its transfer
agent promptly to furnish Parent and Merger Sub with mailing
labels, security position listings, any non-objecting beneficial
owner lists and any available listings or computer files containing
the names and addresses of the record holders of Shares as of the
most recent practicable date and shall promptly furnish Parent and
Merger Sub with such additional available stockholder information
(including, but not limited to, periodic updates of such
information) as Parent, Merger Sub or their agents or
Representatives (as defined in Section 6.3(b) hereof)
may reasonably request for the purpose of communicating the Offer
to the record and beneficial holders of Shares.
(a) Subject
to compliance with applicable Law and the Company Constituent
Documents (as defined in Section 4.1(b) hereof), as of
the Acceptance Time, and at all times thereafter, Parent shall be
entitled to elect or designate such number of directors on the
Company Board (“ Directors ”), rounded up to the
next whole number, as is equal to the product of the total number
of Directors (determined after giving effect to the Directors
elected or appointed pursuant to this sentence) multiplied by the
percentage that the aggregate number of Shares beneficially owned
by Parent and Merger Sub or their respective Affiliates (as defined
in Section 9.3(a) hereof) at such time (including
Shares so accepted for payment pursuant to the Offer and any Top-Up
Shares (as defined in Section 1.5(a) hereof) actually
acquired by Merger Sub) bears to the total number of Shares then
outstanding. In furtherance thereof, the Company shall, upon
request of Parent, subject to compliance with applicable Law and
the Company Constituent Documents, promptly use commercially
reasonable efforts to cause Parent’s designees to be so
elected or designated, including increasing the size of the Company
Board and/or seeking the resignations of one or more incumbent
Directors. At such time, the Company shall, upon request of Parent,
subject to compliance with applicable Law and the Company
Constituent Documents, also promptly use commercially reasonable
efforts to cause individuals designated by Parent to constitute at
least the same percentage (rounded up to the next whole number) as
is on the Company Board of (i) each committee of the Company
Board, (ii) each board of directors (or similar body) of each
Subsidiary of the Company and (iii) each committee (or similar
body) of each such board.
(b) The
Company’s obligations to elect or designate Parent’s
designees to the Company Board shall be subject to Section 14(f) of
the Exchange Act and Rule 14f-1 thereunder. Subject to
Parent’s compliance with the immediately following sentence
in this Section 1.4(b) , the Company shall promptly
take all actions required pursuant to Section 14(f) of the Exchange
Act and Rule 14f-1 in order to fulfill its obligations under
this Section 1.4 , including mailing to stockholders
together with the Schedule 14D-9 the information required
under Section 14(f) and Rule 14f-1 as is necessary to enable
Parent’s designees to be elected or designated to the Company
Board. Parent shall supply to the Company any information with
respect to itself and its officers, Directors and Affiliates to the
extent required for the Company to comply with Section 14(f) of the
Exchange Act and Rule 14f-1. The provisions of
Sections 1.4(a) and (b) are in addition to and shall not
limit any rights that any of Parent, Merger Sub or any of their
respective Affiliates may have as a record holder or beneficial
owner of Shares or a matter of applicable Law with respect to the
election of directors or otherwise. In addition, in connection with
the Offer, the Company shall, and shall cause its Subsidiaries to,
and shall use commercially
5
reasonable
efforts to cause their respective Representatives to, cooperate
with Parent and Merger Sub to disseminate the Offer Documents to
holders of Shares held in or subject to any Company Plan (as
defined in Section 4.11(a) hereof) and to permit such
holder of Shares to tender their Shares in the Offer.
(c) In
the event that Parent’s designees are elected or designated
to the Company Board pursuant to this Section 1.4 ,
then, until the Effective Time (as defined in Section 2.3
hereof), the Company shall use commercially reasonable efforts to
cause the Company Board to maintain at least three
(3) Directors who are members of the Company Board on the date
of this Agreement and who are independent for purposes of
Rule 10A-3 under the Exchange Act (the “ Independent
Directors ”); provided , however , that if
the number of Independent Directors is reduced below three
(3) for any reason, the remaining Independent Director(s)
shall be entitled to nominate an individual or individuals to fill
such vacancy who shall be deemed to be Independent Directors for
purposes of this Agreement or, if no Independent Directors then
remain, the other Directors shall designate three
(3) individuals to fill such vacancies who are independent for
purposes of Rule 10A-3 under the Exchange Act, and such
individuals shall be deemed to be Independent Directors for
purposes of this Agreement. The Company and the Company Board shall
promptly take all action as may be necessary to comply with their
obligations under this Section 1.4(c) . Notwithstanding
anything in this Agreement to the contrary, from and after the
time, if any, that Parent’s designees pursuant to this
Section 1.4 constitute a majority of the Company Board and
prior to the Effective Time, subject to the terms hereof, any
amendment or termination of this Agreement by the Company, any
extension by the Company of the time for the performance of any of
the obligations or other acts of Parent or Merger Sub or waiver of
any of the Company’s rights hereunder, shall require the
concurrence of a majority of the Independent Directors if such
amendment, termination, extension or waiver would reasonably be
expected to have an adverse effect on any holders of Shares other
than Parent or Merger Sub.
Section 1.5
The Top-Up Option .
(a) The
Company hereby irrevocably grants to Merger Sub an option (the
“ Top-Up Option ”), exercisable only upon the
terms and conditions set forth in this Section 1.5 , to
purchase, following the Acceptance Time, that number of Shares (the
“ Top-Up Shares ”) equal to the lowest number of
Shares that, when added to the number of Shares held by Parent and
Merger Sub at the time of exercise, would constitute one share more
than ninety percent (90%) of the total Shares then outstanding
(determined on a fully diluted basis and including the issuance of
the Top-Up Shares), at a price per Share equal to the Offer
Price.
(b) The
Top-Up Option shall be exercisable once in whole and not in part
during the twenty (20) Business Day period immediately
following the Acceptance Time or, if any Subsequent Offering Period
is provided, during the twenty (20) Business Day period
following the expiration date of such Subsequent Offering Period;
provided , however , that in no event shall the
Top-Up Option be exercisable (i) for a number of Shares in
excess of the Company’s then authorized and unissued shares
of common stock (giving effect to Shares reserved for issuance
under the Company Equity Plans (as defined in
Section 3.2(a) hereof) and pursuant to the exercise of
any other securities convertible into or exchangeable into Shares,
if any, as if such Shares were outstanding but not giving effect to
Shares reserved for issuance
6
pursuant to the
Rights, but including as authorized and unissued shares of common
stock, for purposes of this Section 1.5 , any shares held in
the treasury of the Company), (ii) if the issuance of Shares
upon exercise of the Top-Up Option would require approval of the
Company’s stockholders under the rules and regulations of the
Nasdaq Stock Market or (iii) if, after the exercise of the
Top-Up Option, Parent and Merger Sub would not hold a sufficient
number of Shares to cause a short-form merger of the Company
pursuant to Section 253 of the DGCL; provided ,
further , that the Top-Up Option shall automatically
terminate upon the earlier to occur of (i) the Effective Time
and (ii) the termination of this Agreement in accordance with its
terms.
(c) In
the event that Merger Sub wishes to exercise the Top-Up Option,
Merger Sub shall so notify the Company in writing, and shall set
forth in such notice (i) the number of Shares that will be
owned by Parent and Merger Sub immediately preceding the purchase
of the Top-Up Shares and (ii) the place and time for the
closing of the purchase of the Top-Up Shares (the “ Top-Up
Closing ”). The Company shall, as soon as practicable
following receipt of such notice, notify Parent and Merger Sub in
writing of the number of Shares then outstanding and the number of
Top-Up Shares. At the Top-Up Closing, Merger Sub shall pay to the
Company in cash the aggregate purchase price required to be paid
for the Top-Up Shares (calculated by multiplying the number of such
Top-Up Shares by the Offer Price) and the Company shall cause to be
issued to Merger Sub a certificate representing the Top-Up Shares,
which certificate may include any legends required by applicable
securities Laws; provided , however , at
Parent’s election, instead of in cash the aggregate purchase
price for the Top-Up Shares may be paid through the issuance of a
full-recourse promissory note by Parent and Merger Sub, bearing
simple interest at five percent (5%) per annum and due on the first
anniversary of the Top-Up Closing, which promissory note may be
prepaid, in whole or in part, without premium or
penalty.
(d) Merger
Sub acknowledges that the Shares that Merger Sub may acquire upon
exercise of the Top-Up Option will not be registered under the
Securities Act and will be issued in reliance upon an exemption
thereunder for transactions not involving a public offering. Merger
Sub represents and warrants to the Company that Merger Sub is, and
will be upon the purchase of the Top-Up Shares, an
“accredited investor,” as defined in Rule 501 of
Regulation D under the Securities Act of 1933, as amended (the
“ Securities Act ”). Merger Sub agrees that the
Top-Up Option and the Top-Up Shares to be acquired upon exercise of
the Top-Up Option are being and will be acquired by Merger Sub for
its own account, for the purpose of investment and not with a view
to, or for resale in connection with, any distribution thereof
(within the meaning of the Securities Act).
Section 1.6
Short-Form Merger . If, after the consummation of the
Offer and any exercise of the Top-Up Option, the number of Shares
beneficially owned by Parent, Merger Sub and any other Affiliates
of Parent collectively represent at least ninety percent (90%) of
the then-outstanding Shares, Parent shall cause Merger Sub to, and
the Company shall execute and deliver such documents and
instruments and take such other actions as Parent or Merger Sub may
reasonably request, in order to cause the Merger to be completed as
promptly as reasonably practicable without a meeting of the
stockholders of the Company as provided in Section 253 of the
DGCL, and otherwise as provided in Articles II and
III below.
7
Section 2.1
The Merger . Upon the terms and subject to the satisfaction
or, to the extent permitted by applicable Law, waiver of the
conditions set forth in this Agreement and in accordance with the
DGCL, at the Effective Time, Merger Sub shall be merged with and
into the Company. Following the Merger, the separate corporate
existence of Merger Sub shall cease, and the Company shall continue
as the surviving corporation in the Merger (the “
Surviving Corporation ”) and a wholly owned Subsidiary
of Parent.
Section 2.2
Closing . The closing of the Merger (the “
Closing ”) shall take place at 10:00 a.m. local
time, as soon as practicable but in no event later than the second
Business Day following the satisfaction or, to the extent permitted
by applicable Law, waiver of the conditions set forth in
Article VII (other than those conditions that by their
terms are to be satisfied at the Closing, but subject to the
satisfaction or, to the extent permitted by applicable Law, waiver
of those conditions), at the offices of Gibson, Dunn & Crutcher
LLP, 3161 Michelson Drive, Irvine, California 92612, unless another
date, time or place is agreed to in writing by Parent and the
Company. The date on which the Closing occurs is referred to in
this Agreement as the “ Closing Date
.”
Section 2.3
Effective Time . Upon the terms and subject to the
provisions of this Agreement, as soon as practicable on the Closing
Date, the parties shall file a certificate of merger or, if
applicable, a certificate of ownership and merger (as applicable,
the “ Certificate of Merger ”) with the
Secretary of State of the State of Delaware, executed in accordance
with the relevant provisions of the DGCL, and, as soon as
practicable on or after the Closing Date, shall make any and all
other filings or recordings required under the DGCL. The Merger
shall become effective at such time as the Certificate of Merger is
duly filed with the Secretary of State of the State of Delaware or
at such other date or time as Parent and the Company may agree and
specify in the Certificate of Merger (the time the Merger becomes
effective being the “ Effective Time
”).
Section 2.4
Effects of the Merger . The Merger shall have the effects
set forth in this Agreement and in the relevant provisions of the
DGCL. Without limiting the generality of the foregoing, and subject
thereto, at the Effective Time, all the property, rights,
privileges, powers and franchises of the Company and Merger Sub
shall vest in the Surviving Corporation, and all debts, liabilities
and duties of the Company and Merger Sub shall become the debts,
liabilities and duties of the Surviving Corporation.
Section 2.5
Certificate of Incorporation; Bylaws .
(a) At
the Effective Time, the certificate of incorporation of the
Surviving Corporation shall be amended to be identical to the
certificate of incorporation of Merger Sub (as in effect
immediately prior to the Effective Time), except that
Article I thereof shall read in its entirety as
follows: “The name of the Corporation is I-Flow
Corporation.” Such certificate of incorporation shall be the
certificate of incorporation of the Surviving Corporation until
thereafter amended in accordance with the provisions thereof and
applicable Law.
8
(b) At
the Effective Time, the bylaws of the Surviving Corporation shall
be amended to be identical to the bylaws of Merger Sub (as in
effect immediately prior to the Effective Time), except that such
bylaws shall reflect that the name of Surviving Corporation is
I-Flow Corporation. Such bylaws shall be the bylaws of the
Surviving Corporation until thereafter amended in accordance with
the provisions thereof and applicable Law.
Section 2.6
Directors . The directors of Merger Sub immediately prior to
the Effective Time shall be the directors of the Surviving
Corporation until the earlier of their resignation or removal or
until their respective successors are duly elected and
qualified.
Section 2.7
Officers . The officers of Merger Sub immediately prior to
the Effective Time shall be the officers of the Surviving
Corporation until the earlier of their resignation or removal or
until their respective successors are duly elected and
qualified.
ARTICLE III
EFFECT ON THE CAPITAL STOCK OF THE
CONSTITUENT CORPORATIONS; EXCHANGE OF CERTIFICATES
Section 3.1
Conversion of Capital Stock . At the Effective Time, by
virtue of the Merger and without any action on the part of the
Company, Parent, Merger Sub or the holders of any shares of capital
stock of the Company, Parent or Merger Sub:
(a) Each
Share issued and outstanding immediately prior to the Effective
Time (other than Shares to be canceled in accordance with
Section 3.1(b) and other than any Dissenting Shares as
defined in Section 3.5 hereof), together with the
associated Rights, shall thereupon be converted automatically into
and shall thereafter represent the right to receive $12.65 net in
cash (the “ Offer Price ”), without interest,
and subject to deduction for any required withholding Tax (as
defined in Section 4.14(l)(i) hereof) (the “
Merger Consideration ”). From and after the Effective
Time, all such Shares shall no longer be outstanding and shall
automatically be canceled and shall cease to exist, and each holder
of a Share shall cease to have any rights with respect thereto,
except the right to receive the Merger Consideration therefor upon
the surrender of such Share in accordance with
Section 3.3.
(b) Each
Share held in the treasury of the Company or owned, directly or
indirectly, by Parent or Merger Sub immediately prior to the
Effective Time shall automatically be canceled and retired and
shall cease to exist, and no consideration shall be delivered in
exchange therefor.
(c) Each
share of common stock, par value $0.001 per share, of Merger Sub
issued and outstanding immediately prior to the Effective Time
shall be converted into and become one (1) validly issued, fully
paid and non-assessable share of common stock, par value $0.001 per
share, of the Surviving Corporation.
Section 3.2
Treatment of Options, Restricted Stock Units and Restricted
Stock .
(a) Except
as set forth in Section 3.2 of the Company Disclosure Letter,
at the Effective Time, each option (each, a “ Company
Stock Option ”) to purchase Shares granted under any
employee, consultant, representative or Director stock option,
stock purchase or equity
9
compensation
plan, arrangement or agreement of the Company or its Subsidiaries
(collectively, the “ Company Equity Plans ”),
whether vested or unvested, that is outstanding immediately prior
to the Effective Time shall be canceled and, in exchange therefor
(and full satisfaction thereof), the Surviving Corporation shall
pay, and Parent shall cause the Surviving Corporation to pay, to
each Person who, at the time of such cancellation, was holding any
such canceled Company Stock Option as soon as practicable following
the Effective Time an amount in cash (without interest, and subject
to deduction for any required withholding Taxes) equal to the
product of (i) the excess (if any) of the Merger Consideration
over the exercise price per Share under such Company Stock Option
and (ii) the number of Shares subject to such Company Stock
Option; provided , that if the exercise price per Share
under any such Company Stock Option is equal to or greater than the
Merger Consideration, then such Company Stock Option shall be
canceled without any cash payment being made in respect
thereof.
(b) At
the Effective Time, each restricted stock unit (each, a “
Company RSU ”) granted under any Company Equity Plan
that is outstanding immediately prior to the Effective Time shall
be canceled and, in exchange therefor (and full satisfaction
thereof), the Surviving Corporation shall pay, and Parent shall
cause the Surviving Corporation to pay, to each Person who, at the
time of such cancellation, was holding any such canceled Company
RSU as soon as practicable following the Effective Time an amount
in cash (without interest, and subject to deduction for any
required withholding Taxes) equal to the product of (i) the
Merger Consideration and (ii) the number of such canceled
Company RSUs formerly held by such Person.
(c) Immediately
prior to the Effective Time, all unvested restricted stock (“
Unvested Restricted Stock ”) granted under the Company
Equity Plans outstanding immediately prior to the Effective Time
shall vest ( i.e. , all restrictions on the restricted stock
shall lapse) and, along with all other vested restricted stock,
shall be treated in accordance with Section 3.1(a)
.
(d) Prior
to the Effective Time, the Company shall adopt such resolutions and
take such appropriate action as may be reasonably required to
effectuate the provisions of this Section 3.2 . For the
avoidance of doubt, to the extent any Company Stock Option, Company
RSU or Unvested Restricted Stock will become vested pursuant to its
terms (as in effect on the date hereof), including by virtue of any
vesting acceleration provision included in such terms, prior to the
Effective Time, then nothing in this Section 3.2(d) shall be
construed as requiring such vesting to be delayed until the
Effective Time.
(e) Prior
to the Effective Time, upon the request of Parent, the Company
shall use commercially reasonable efforts to cause the termination
of the Company Stock Option set forth in Section 3.2(a) of the
Company Disclosure Letter; provided , however , that
any action to be taken by the Company pursuant to this
Section 3.2(e) shall require the prior written consent
of Parent (not to be unreasonably withheld, conditioned or
delayed).
Section 3.3
Exchange and Payment .
(a) Prior
to the Effective Time, Merger Sub shall enter into an agreement
with the Company’s transfer agent or other exchange agent
selected by Parent and reasonably
10
acceptable to
the Company (the “ Exchange Agent ”) to receive
the Merger Consideration to which stockholders of the Company shall
become entitled pursuant to this Article III . At or
prior to the Effective Time, Parent shall deliver or cause to be
delivered to the Exchange Agent cash in an amount sufficient to pay
the aggregate Merger Consideration in accordance with
Section 3.1(a) (the “ Exchange Fund
”). The Exchange Fund shall not be used for any purpose other
than to fund payments due pursuant to Section 3.1(a) ,
except as provided in this Agreement. Parent and the Surviving
Corporation shall pay all charges and expenses, including those of
the Exchange Agent, incurred by them in connection with the
exchange of Shares for the Merger Consideration and other amounts
contemplated by this Article III .
(b) As
soon as reasonably practicable after the Effective Time, the
Surviving Corporation shall cause the Exchange Agent to mail to
each holder of record of (i) a certificate or certificates
(“ Certificates ”) that immediately prior to the
Effective Time represented outstanding Shares or
(ii) uncertificated Shares represented by book-entry (“
Book-Entry Shares ”) which, in each case, were
converted into the right to receive the Merger Consideration with
respect thereto pursuant to Section 3.1(a) , (A) a
form of letter of transmittal (which shall specify that delivery
shall be effected, and risk of loss and title to the Certificates
or Book-Entry Shares held by such Person (as defined in
Section 9.3(f) hereof) shall pass, only upon proper
delivery of the Certificates to the Exchange Agent or, in the case
of Book-Entry Shares, upon adherence to the procedures set forth in
the letter of transmittal, as applicable, and shall be in customary
form and contain such other provisions as Parent or the Exchange
Agent may reasonably specify) and (B) customary instructions
for use in effecting the surrender of Certificates or Book-Entry
Shares in exchange for the Merger Consideration payable with
respect thereto pursuant to Section 3.1(a) and
customary instructions consistent with Section 3.3(e) for
use in effecting payment for lost, stolen or destroyed
Certificates. Upon surrender of a Certificate or Book-Entry Share
to the Exchange Agent, together with such letter of transmittal,
properly completed and duly executed, and such other documents as
the Exchange Agent may reasonably require, the holder of such
Certificate or Book-Entry Share shall be entitled to receive in
exchange therefor the Merger Consideration for each Share formerly
represented by such Certificate or Book-Entry Share (in each case,
subject to deduction for any required withholding Taxes), and such
Certificate or Book-Entry Share shall forthwith be canceled. No
interest shall be paid or shall accrue on any cash payable upon
surrender of any Certificate or Book-Entry Share. In the event that
the Merger Consideration is to be paid to a Person other than the
Person in whose name any Certificate is registered, it shall be a
condition of payment that the Certificate so surrendered shall be
properly endorsed or otherwise in proper form for transfer, that
the signatures on such Certificate or any related stock power shall
be properly guaranteed and that the Person requesting such payment
shall pay any transfer or other Taxes required by reason of such
payment to a Person other than the registered holder of such
Certificate or establish to the satisfaction of the Surviving
Corporation that such Taxes have been paid or are not applicable.
Until surrendered as contemplated by this Section 3.3 , each
Certificate or Book-Entry Share shall be deemed at any time after
the Effective Time to represent only the right to receive upon such
surrender or transfer the Merger Consideration pursuant to
Section 3.1(a) payable in respect of Shares theretofore
represented by such Certificate or Book-Entry Shares, as
applicable, without any interest thereon.
(c) The
payment of the applicable Merger Consideration upon the surrender
for exchange of Certificates or Book-Entry Shares in accordance
with the terms of this Article III
11
shall be deemed
to have been delivered and paid in full satisfaction of all rights
pertaining to the Shares (including the associated Rights) formerly
represented by such Certificates or Book-Entry Shares. At the
Effective Time, the stock transfer books of the Company shall be
closed and there shall be no further registration of transfers on
the stock transfer books of the Surviving Corporation of the Shares
that were outstanding immediately prior to the Effective Time. If,
after the Effective Time, Certificates are presented to the
Surviving Corporation or the Exchange Agent for transfer or
transfer is sought for Book-Entry Shares, such Certificates or
Book-Entry Shares shall be canceled and exchanged as provided in
this Article III , subject to applicable Law in the
case of Dissenting Shares (as defined in Section 3.5
hereof). The Exchange Agent shall invest the cash included in the
Exchange Fund as directed by Parent; provided ,
however , that no such investment income or gain or loss
thereon shall affect the amounts payable to holders of Shares. Any
interest and other income resulting from such investments shall be
the sole and exclusive property of Parent payable to Parent upon
its request, and no part of such earnings shall accrue to the
benefit of holders of Shares.
(d) Any
portion of the Exchange Fund (and any interest or other income
earned thereon) that remains undistributed to the holders of
Certificates or Book-Entry Shares nine (9) months after the
Effective Time shall be delivered to the Surviving Corporation or
one of its Affiliates upon demand, and any holders of Certificates
or Book-Entry Shares who have not theretofore complied with this
Article III shall thereafter look only to the Surviving
Corporation, as general creditors thereof, for payment of the
Merger Consideration with respect to Shares formerly represented by
such Certificate or Book-Entry Share, without interest.
Notwithstanding the foregoing, neither the Surviving Corporation
nor any of its Affiliates shall be liable to any holder of Shares
for any amount paid to a public official pursuant to applicable
abandoned property, escheat or similar Laws. Any amounts remaining
unclaimed by holders of Shares two (2) years after the Effective
Time (or such earlier date immediately prior to such time when the
amounts would otherwise escheat to or become property of any
Governmental Entity (as defined in Section 4.4(b)
hereof)) shall become, to the extent permitted by applicable Law,
the property of the Surviving Corporation free and clear of any
claims or interest of any Person previously entitled
thereto.
(e) If
any Certificate shall have been lost, stolen or destroyed, upon the
making of an affidavit, in form and substance reasonably acceptable
to Parent, of that fact by the Person claiming such Certificate to
be lost, stolen or destroyed and, if required by Parent or the
Exchange Agent, the posting by such Person of a bond in such amount
as Parent or the Exchange Agent may determine is reasonably
necessary as indemnity against any claim that may be made against
it or the Surviving Corporation with respect to such Certificate,
the Exchange Agent will deliver in exchange for such lost, stolen
or destroyed Certificate the Merger Consideration payable in
respect thereof pursuant to this Agreement.
(f) Any
portion of the Merger Consideration made available to the Exchange
Agent pursuant to Section 3.3(a) to pay for Dissenting
Shares for which appraisal rights have been perfected shall be
returned to the Surviving Corporation or one of its Affiliates,
upon demand.
Section 3.4
Withholding Rights . Parent, the Surviving Corporation or
the Exchange Agent shall be entitled to deduct and withhold from
the consideration otherwise payable to any
12
holder of
Shares, Company Stock Options, Company RSUs, or restricted stock or
otherwise pursuant to this Agreement such amounts as Parent, the
Surviving Corporation or the Exchange Agent is required to deduct
and withhold with respect to the making of such payment under the
Internal Revenue Code of 1986, as amended (the “ Code
”), or any provision of state, local or foreign tax Law. To
the extent that amounts are so withheld and paid over to the
appropriate taxing authority by Parent, the Surviving Corporation
or the Exchange Agent, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to the Person in
respect of which such deduction and withholding was
made.
Section 3.5
Dissenting Shares . Notwithstanding anything in this
Agreement to the contrary, Shares issued and outstanding
immediately prior to the Effective Time that are held by any holder
who has not voted in favor of the Merger and who is entitled to
demand and properly demands appraisal of such Shares pursuant to,
and who complies in all respects with, Section 262 of the DGCL
(“ Dissenting Shares ”) shall not be converted
into the right to receive the Merger Consideration, unless and
until such holder shall have failed to perfect, or shall have
effectively withdrawn or lost, such holder’s right to
appraisal under the DGCL. Dissenting Shares shall be treated in
accordance with Section 262 of the DGCL. If any such holder
fails to perfect or withdraws or loses any such right to appraisal,
then each such Share of such holder shall thereupon be converted
into and become exchangeable only for the right to receive, as of
the later of the Effective Time and the time that such right to
appraisal has been irrevocably lost, withdrawn or expired, the
Merger Consideration in accordance with Section 3.1(a)
. Prior to the Effective Time, the Company shall promptly notify
Parent of any demands for appraisal of any Shares, attempted
withdrawals of such notices or demands and any other instruments
received by the Company relating to rights to appraisal, and Parent
shall have the right to participate in and direct all negotiations
and proceedings with respect to such demands. Prior to the
Effective Time, the Company shall not, without the prior written
consent of Parent, make any payment with respect to, settle or
offer to settle, or approve any withdrawal of any such
demands.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
Except as
disclosed or reflected in the Company SEC Documents (as defined in
Section 4.5(a) hereof) filed or furnished by the Company and
publicly available prior to the date of this Agreement (without
giving effect to any amendment to any such Company SEC Documents
filed on or after the date hereof and excluding any disclosures
therein that constitute forward-looking statements or other
statements that are cautionary, predictive or forward-looking in
nature (but, for the purpose of clarification, including and giving
effect to any factual or historical statements included in any such
forward-looking statements or other statements that are cautionary,
predictive or forward-looking in nature)) and except as set forth
in the disclosure letter delivered by the Company to Parent prior
to the execution and delivery of this Agreement (the “
Company Disclosure Letter ”) (it being agreed that
disclosure of any information in a particular section or subsection
of the Company Disclosure Letter shall be deemed disclosure with
respect to any other section or subsection of this Agreement to
which the relevance of such information is reasonably apparent),
the Company represents and warrants to Parent and Merger Sub as
follows:
13
Section 4.1
Organization, Standing and Power .
(a) Section 4.1
of the Company Disclosure Letter contains a complete and accurate
list, for the Company and each of its Subsidiaries, of its name,
its jurisdiction of organization, the Company’s percentage
ownership for any Subsidiary that is not a wholly owned Subsidiary
and the jurisdictions in which such entity is qualified to conduct
business. Each of the Company and its Subsidiaries (each of the
Company and its Subsidiaries is referred to herein as an “
Acquired Company ” and, collectively, as the “
Acquired Companies ”) (i) is an entity duly
organized, validly existing and in good standing (with respect to
jurisdictions that recognize such concept) under the Laws of the
jurisdiction of its organization, (ii) has all requisite
corporate or similar power and authority to own, lease and operate
its properties and assets and to carry on its business as now being
conducted and (iii) is duly qualified or licensed to do
business and is in good standing (with respect to jurisdictions
that recognize such concept) in each jurisdiction in which the
nature of its business or the ownership, leasing or operation of
its properties makes such qualification or licensing necessary,
except for any such failures that individually or in the aggregate
do not have, and would not reasonably be expected to have, a
Material Adverse Effect.
For purposes of
this Agreement, “ Material Adverse Effect ”
means any event, change, circumstance, effect or state of facts
that, either individually or in the aggregate: (A) is
materially adverse to the business, assets, financial condition or
results of operations of the Company and its Subsidiaries, taken as
a whole, other than the effects of any event, change, circumstance,
effect or state of facts arising out of or attributable to any of
the following, either alone or in combination: (1) general
changes, trends or developments in any of the industries in which
the Company or any of its Subsidiaries operates, (2) changes
in global, national or regional political conditions (including the
outbreak of war or acts of terrorism) or in general economic,
business, regulatory, political or market conditions or in national
or global financial markets, (3) international calamity
directly or indirectly involving the United States, national
calamity, an act of war (whether or not declared), sabotage,
terrorism, military actions or the escalation thereof, an act of
God or other force majeure events, (4) any actions required
under this Agreement to obtain any approval or authorization under
applicable Laws for the consummation of the Merger,
(5) changes in any applicable Laws or applicable accounting
regulations or principles or interpretations thereof,
(6) changes in the price or trading volume of the
Company’s stock (provided that the events, changes,
circumstances, effects or state of facts underlying any such
changes shall not be excluded in determining whether there has been
a Material Adverse Effect, unless otherwise excluded by any one or
more of clauses (1) through (5), inclusive, or
(7) through (15), inclusive, of this paragraph), (7) any
failure by the Company or any Subsidiary to meet any estimates or
expectations of the Company’s or such Subsidiary’s
revenue, earnings or other financial performance or results of
operations for any period, or any failure by the Company or any of
its Subsidiaries to meet its own internal or published projections,
budgets, plans or forecasts of its revenues, earnings, cash flows
or other financial performance or results of operations (provided
that the events, changes, circumstances, effects or state of facts
underlying any such failures shall not be excluded in determining
whether there has been a Material Adverse Effect, unless otherwise
excluded by any one or more of clauses (1) through (6),
inclusive, or (8) through (15), inclusive, of this paragraph),
(8) the announcement or pendency of this Agreement and the
transactions contemplated hereby, or the performance of this
Agreement and the transactions contemplated hereby, including the
initiation of litigation, or the
14
failure to give
any consent, by any Person with respect to this Agreement, and
including any termination of, reduction in or similar negative
impact on relationships, contractual or otherwise, with any
customers, suppliers, licensors, distributors, partners,
consultants or employees of the Company and its Subsidiaries due to
the announcement and performance of this Agreement or the identity
of the parties to this Agreement, or the performance of this
Agreement and the transactions contemplated hereby, (9) the
termination or resignation of any director, executive officer,
other employee or consultant of the Company or any of its
Subsidiaries, (10) any action taken (or omitted to be taken)
by the Company, or which the Company causes to be taken (or omitted
to be taken) by any of its Subsidiaries, in each case which is
required by or resulting from or arising in connection with this
Agreement, (11) any actions taken (or omitted to be taken) at
the written request of or consented to in writing by Parent, Merger
Sub or their Affiliates or Representatives, (12) any increase
in the cost or availability of financing to Parent or Merger Sub,
(13) any legal, regulatory or other action or development
(including the establishment of accounting reserves) relating to or
arising out of chondrolysis or any of the matters set forth in
Section 4.9 of the Company Disclosure Letter, including new
claims based on the same or similar subject matter, the outcome of
existing claims and any amendment to any existing complaint, (14)
government favoritism of products or changes in reimbursement
procedures (including in connection with comparative effectiveness
research conducted by or on behalf of the United States Department
of Health and Human Services, including the results thereof) or
(15) the business of InfuSystem Holdings, Inc. or its
Affiliates, including its results of operations and financial
liquidity (in the case of each of clauses (1), (2) and (3), so
long as such effects do not disproportionately impact the Company
and its Subsidiaries relative to other participants in the industry
or industries in which the Company and its Subsidiaries conduct
their business) or (B) prevents, materially impedes or
materially interferes with the ability of the Company to perform
its material obligations under this Agreement or the ability of the
Company to consummate the transactions contemplated hereby. For the
avoidance of doubt, references to the defined term “Material
Adverse Effect” herein shall always include the exceptions
described in clauses (1) through (15) above,
inclusive.
(b) The
Company has delivered or made available to Parent true, correct and
complete copies of (i) the certificate of incorporation,
bylaws and other charter or organizational documents of each of the
Acquired Companies, including all amendments thereto and
(ii) the minutes and other records of the meetings and other
proceedings (including any actions taken by written consent or
otherwise without a meeting) of the equity holders of each of the
Acquired Companies, the board of directors or managers of each of
the Acquired Companies and all committees of the board of directors
or managers of each of the Acquired Companies, in each case since
January 1, 2005, except for such portions of the minutes of
the boards of directors of the Acquired Companies that relate to
the consideration by such directors of the transactions
contemplated hereby and as set forth in Section 4.1(b) of the
Company Disclosure Letter (the items described in clauses
(i) and (ii) above, collectively, the “ Company
Constituent Documents ”). The Company Constituent
Documents are in full force and effect on the date hereof. The
Company has no Subsidiaries, except for the entities identified in
Section 4.1 of the Company Disclosure Letter. None of the
Acquired Companies has any equity interest in, or any interest
convertible into or exchangeable or exercisable for any equity
interest in, any other entity, other than those set forth in
Section 4.1 of the Company Disclosure Letter.
15
Section 4.2
Capital Stock .
(a) The
authorized capital stock of each Acquired Company and the issued
and outstanding capital stock of each Acquired Company as of the
date hereof are set forth in Section 4.2(a) of the Company
Disclosure Letter. Each of the outstanding shares of capital stock
or other equity interests of each Acquired Company is, and the
shares of capital stock that may be issued pursuant to Company
Stock Options and Company RSUs will be (when issued in accordance
with the terms thereof), duly authorized, validly issued, fully
paid and nonassessable. Except as set forth in Section 4.2(a)
of the Company Disclosure Letter, all shares or other equity
interests of the Subsidiaries of the Company are owned by the
Company or another wholly owned Subsidiary of the Company free and
clear of all security interests, liens, claims, pledges,
agreements, limitations in voting rights, charges, mortgages or
other encumbrances (collectively, “ Liens ”) of
any nature whatsoever, except for Permitted Liens (as defined in
Section 4.17 hereof).
(b) Except
as set forth in Section 4.2(b) of the Company Disclosure
Letter, as of the date of this Agreement, (i) there are not
outstanding or authorized (A) any securities of any Acquired
Company convertible into or exchangeable for shares of capital
stock or voting securities of any Acquired Company or
(B) options, calls, warrants, pre-emptive rights,
anti-dilution rights or other rights, rights agreements,
stockholder rights plans, agreements, arrangements or commitments
of any character relating to the issued or unissued capital stock,
voting securities or securities convertible into or exchangeable
for capital stock or voting securities of any Acquired Company
(except for the Support Agreements), (ii) there are no
outstanding obligations of any Acquired Company to repurchase,
redeem or otherwise acquire any capital stock, voting securities or
securities convertible into or exchangeable for capital stock or
voting securities of any Acquired Company or to provide a material
amount of funds to, or make any material investment (in the form of
a loan, capital contribution or otherwise) in, any Subsidiary,
(iii) no Acquired Company has issued phantom stock or other
contractual rights the value of which is determined in whole or in
part by the value of any capital stock of any Acquired Company and
there are no outstanding stock appreciation rights issued by any
Acquired Company with respect to the capital stock of any Acquired
Company, (iv) except for the Support Agreements, there are no
voting trusts or other agreements or understandings to which any of
the Acquired Companies or, to the knowledge of the Company, any of
their respective officers and directors is a party with respect to
the voting of capital stock of any Acquired Company, and
(v) there are no outstanding bonds, debentures, notes or other
indebtedness of any Acquired Company having the right to vote (or
convertible into, or exchangeable for, securities having the right
to vote) on any matter on which the stockholders or other equity
holders of the Acquired Companies may vote.
(c) As
of the date hereof, 1,301,039 Shares are subject to issuance
pursuant to Company Stock Options granted and outstanding under the
Company Equity Plans. Section 4.2(c) of the Company Disclosure
Letter sets forth the following information with respect to each
Company Stock Option outstanding as of the date of this Agreement:
(i) the Company Equity Plan pursuant to which such Company
Stock Option was granted; (ii) the name of the holder of such
Company Stock Option; (iii) the number of shares of Company common
stock subject to such Company Stock Option; (iv) the exercise
price of such Company Stock Option; (v) the date on which such
Company Stock Option was granted; (vi) the extent to which
such Company Stock Option is vested and exercisable as of the date
of this Agreement and the times and extent to which such Company
Stock Option is scheduled to become vested and
16
exercisable
after the date of this Agreement; and (vii) the date on which
such Company Stock Option expires. Except as set forth in
Section 4.2(c) of the Company Disclosure Letter, the exercise
price of each Company Stock Option is equal to or greater than the
fair market value of the Shares subject to such Company Stock
Option (determined as of the date such Company Stock Option was
granted).
(d) As
of the date hereof, 711,430 Shares are subject to issuance pursuant
to Company RSUs granted and outstanding under the Company Equity
Plans. Section 4.2(d) of the Company Disclosure Letter sets
forth the following information with respect to each Company RSU
outstanding as of the date of this Agreement: (i) the Company
Equity Plan pursuant to which such Company RSU was granted;
(ii) the name of the holder of such Company RSU;
(iii) the number of shares of Company common stock subject to
such Company RSU; (iv) the date on which such Company RSU was
granted; and (v) the extent to which such Company RSU is
vested as of the date of this Agreement and the times and extent to
which such Company RSU is scheduled to become vested after the date
of this Agreement.
(e) As
of the date hereof, there are 248,052 Shares that constitute
Unvested Restricted Stock, which are reflected in the outstanding
capital stock of the Company set forth in Section 4.2(a) of
the Company Disclosure Letter. Section 4.2(e) of the Company
Disclosure Letter sets forth the following information with respect
to each share of Unvested Restricted Stock outstanding as of the
date of this Agreement: (i) the Company Equity Plan pursuant
to which such Unvested Restricted Stock was granted; (ii) the
name of the holder of such Unvested Restricted Stock;
(iii) the number of shares of Company common stock subject to
such Unvested Restricted Stock; (iv) the date on which such
Unvested Restricted Stock was granted; and (v) the dates on
which such Unvested Restricted Stock is scheduled to
vest.
(f) The
Company has made available to Parent accurate and complete copies
of all stock equity plans pursuant to which the Company has granted
Company Stock Options, Company RSUs and Unvested Restricted Stock
and the forms of all award agreements evidencing such Company Stock
Options, Company RSUs and Unvested Restricted Stock. There are no
outstanding options to purchase Shares, restricted Shares or
restricted stock units associated with Shares that were issued
other than pursuant to any Company Plan and set forth in
Sections 4.2(c), (d) and (e) of the Company
Disclosure Letter.
Section 4.3
Authority . The Company has all necessary corporate power
and authority to execute and deliver this Agreement, to perform its
obligations hereunder and, subject, in the case of the Merger, to
the adoption and approval of this Agreement and the Merger by the
holders of at least a majority of the outstanding stock of the
Company entitled to vote thereon (the “ Company
Stockholder Approval ”), to consummate the transactions
contemplated hereby. The execution, delivery and performance of
this Agreement by the Company and the consummation by the Company
of the transactions contemplated hereby have been duly authorized
by all necessary corporate action on the part of the Company and no
other corporate proceedings on the part of the Company are
necessary to approve this Agreement or to consummate the
transactions contemplated hereby, subject, in the case of the
consummation of the Merger, to obtaining the Company Stockholder
Approval and to the filing of the Certificate of Merger with the
Secretary of State of the State of Delaware as required by the
DGCL. This Agreement has been duly executed and delivered by the
Company and, assuming the due
17
authorization,
execution and delivery by Parent and Merger Sub, constitutes a
legal, valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms (except to the
extent that enforceability may be limited by applicable bankruptcy,
insolvency, moratorium, reorganization or similar Laws affecting
the enforcement of creditors’ rights generally or by general
principles of equity). As of the date hereof, the Company Board, at
a meeting duly called and held, has unanimously approved and
declared advisable this Agreement and the transactions contemplated
hereby and, subject to Section 6.3 , has resolved to
recommend that the Company’s stockholders accept the Offer,
tender their Shares to Merger Sub pursuant to the Offer and, if
necessary under applicable Law, adopt this Agreement and approve
the Merger and the other transactions contemplated hereby in
accordance with the provisions of the DGCL, which resolutions have
not been rescinded, modified or withdrawn in any way except, if
applicable, to the extent permitted by Section 6.3
.
Section 4.4
No Conflict; Consents and Approvals .
(a) The
execution, delivery and performance of this Agreement by the
Company, and the consummation by the Company of the transactions
contemplated hereby, do not and will not (i) conflict with or
violate the Company Constituent Documents, (ii) assuming that
all consents, approvals and authorizations contemplated by clauses
(i) through (iv) of subsection (b) below have been
obtained and all filings described in such clauses have been made,
conflict with or violate any statute, law, ordinance, rule,
regulation, order, judgment or decree (collectively, “
Law ”) or any settlement, injunction or award of any
Governmental Entity, in each case that is applicable to the Company
or any of its Subsidiaries or by which any of their respective
properties are bound, (iii) except as set forth in
Section 4.4(a) of the Company Disclosure Letter, result in any
breach or violation of, or constitute a default (or an event which
with notice or lapse of time or both would become a default), or
result in a right of guaranteed payment or loss of a benefit under,
or give rise to any right of termination, cancellation, amendment
or acceleration of, any Material Contract (as defined in
Section 4.15 hereof) to which the Company or any of its
Subsidiaries is a party or by which the Company or any of its
Subsidiaries or any of their respective properties are bound,
(iv) result in any breach or violation of any Company Plan,
including any award agreement thereunder (it being understood that
any rights arising under and pursuant to the terms of any Company
Plan in connection with the transactions contemplated by this
Agreement shall not be considered a breach or violation of such
Company Plan), or (v) result in the creation of any Lien upon
any of the properties or assets of the Acquired Companies, except,
in the case of clauses (ii), (iii), (iv) and (v), for any such
conflict, breach, violation, default, loss, right or other
occurrence that individually or in the aggregate does not have, and
would not reasonably be expected to have, a Material Adverse
Effect.
(b) The
execution, delivery and performance of this Agreement by the
Company, and the consummation by the Company of the transactions
contemplated hereby, do not and will not require any consent,
approval, order, license, authorization or permit of, action by,
filing, registration or declaration with or notification to, any
governmental or regulatory (including stock exchange) authority,
agency, court, commission or other governmental body (each, a
“ Governmental Entity ”), except for
(i) such filings as required under applicable requirements of
the Exchange Act (and the rules and regulations promulgated
thereunder) and under state securities and “blue sky”
Laws, (ii) the filings required under the
Hart-Scott-Rodino
18
Antitrust
Improvements Act of 1976, as amended (the “ HSR Act
”) and any filings required under the applicable requirements
of antitrust or other competition Laws of jurisdictions other than
the United States or investment Laws relating to foreign ownership
(“ Foreign Antitrust Laws ”), (iii) such
filings as are necessary to comply with the applicable requirements
of the Nasdaq Stock Market, (iv) the filing with the Secretary
of State of the State of Delaware of the Certificate of Merger as
required by the DGCL and (v) any such consent, approval,
authorization, permit, action, filing or notification the failure
of which to make or obtain individually or in the aggregate does
not have, and would not reasonably be expected to have, a Material
Adverse Effect. 3
Section 4.5
SEC Reports; Financial Statements .
(a) Except
as set forth in Section 4.5(a) of the Company Disclosure
Letter, the Company has filed or furnished all forms, reports,
statements, schedules, certifications and other documents
(including all exhibits, amendments and supplements thereto)
required to be filed by it with the SEC since January 1, 2006
(all such forms, reports, statements, schedules, certificates and
other documents filed or furnished since January 1, 2006,
collectively, the “ Company SEC Documents ”).
Except as set forth in Section 4.5(a) of the Company
Disclosure Letter, as of their respective dates, or, if amended, as
of the date of the last such amendment, each of the Company SEC
Documents complied as to form in all material respects with the
applicable requirements of the Securities Act, the Exchange Act and
SOX (as defined in Section 4.5(d) hereof), and the
applicable rules and regulations promulgated thereunder, as the
case may be, each as in effect on the date so filed. Except as set
forth in Section 4.5(a) of the Company Disclosure Letter, and
except to the extent that information in any Company SEC Document
has been revised or superseded by a subsequently filed Company SEC
Document prior to the date hereof, none of the Company SEC
Documents contains any untrue statement of a material fact or omits
to state a material fact required to be stated or incorporated by
reference therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were
made, not misleading. No Subsidiary of the Company is subject to
the periodic reporting requirements of the Exchange Act or is or
has been otherwise required to file any form, report, statement,
schedule, certificate or other document with the SEC, any foreign
Governmental Entity that performs a similar function to that of the
SEC or any securities exchange or quotation system.
(b) Except
as set forth in Section 4.5(b) of the Company Disclosure
Letter, the audited consolidated financial statements of the
Company (including any related notes thereto) that are included in
the Company SEC Documents (i) complied as to form in all
material respects with the published rules and regulations of the
SEC applicable thereto, (ii) have been prepared in accordance
with United States generally accepted accounting principles
(“ GAAP ”) applied on a consistent basis
throughout the periods involved (except as may be indicated in the
notes thereto) and (iii) fairly present in all material
respects the consolidated financial position of the Company and its
Subsidiaries at the respective dates thereof and the results of
their operations and cash flows for the periods indicated. Except
as set forth in Section 4.5(b) of the Company Disclosure
Letter, the unaudited consolidated financial statements of the
Company (including any related notes thereto) that are included in
the Company SEC Documents (x) complied as to form in all
material respects with the published rules and regulations of the
SEC applicable thereto, (y) have been prepared in accordance
with GAAP applied on a consistent basis throughout the periods
involved (except as may be indicated in the notes thereto or may be
permitted by the SEC under
19
the Exchange
Act) and (z) fairly present in all material respects the
consolidated financial position of the Company and its Subsidiaries
as of the respective dates thereof and the results of their
operations and cash flows for the periods indicated (subject to
normal period-end adjustments).
(c) The
Company (i) maintains “disclosure controls and
procedures” and “internal control over financial
reporting” (as such terms are defined in paragraphs
(e) and (f), respectively, of Rule 13a-15 under the Exchange
Act) as required by Rule 13a-15 under the Exchange Act, and
(ii) has disclosed, based on its most recent evaluation prior
to the date hereof, to the Company’s outside auditors and the
audit committee of the Company Board (A) any significant
deficiencies and material weaknesses in the design or operation of
such internal controls over financial reporting that are reasonably
likely to adversely affect in any material respect the
Company’s ability to record, process, summarize and report
financial information and (B) any fraud, whether or not
material, that involves management or other employees who have a
significant role in the Company’s internal controls over
financial reporting. The Company’s “disclosure controls
and procedures” are reasonably designed to ensure that all
material information (both financial and non-financial) required to
be disclosed by the Company in the reports that it files or
furnishes under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the rules and
forms of the SEC, and that all such information is accumulated and
communicated to the Company’s management as appropriate to
allow timely decisions regarding required disclosure and to make
the certifications of the Chief Executive Officer and Chief
Financial Officer of the Company required under the Exchange Act
and SOX with respect to such reports. The Company’s
management has completed an assessment of the effectiveness of the
Company’s internal control over financial reporting in
compliance with the requirements of Section 404 of SOX for the
year ended December 31, 2008, and such assessment concluded
that such controls were effective.
(d) The
then-acting Chief Executive Officer and the Chief Financial Officer
of the Company have signed, and the Company has furnished to the
SEC, all certifications required by Rule 13a-14 or 15d-14
under the Exchange Act and Sections 302 and 906 of the
Sarbanes-Oxley Act of 2002 (“ SOX ”) and the
statements contained in such certifications are accurate; such
certifications contain no qualifications or exceptions to the
matters certified therein and have not been modified or withdrawn;
and neither the Company nor any of its officers has received notice
from any Governmental Entity questioning or challenging the
accuracy, completeness, form or manner of filing or submission of
such certifications.
Section 4.6
No Undisclosed Liabilities . Except as set forth in
Section 4.6 of the Company Disclosure Letter, neither the
Company nor any of its Subsidiaries has any liabilities or
obligations of any nature, whether or not accrued, contingent or
otherwise, that would be required by GAAP to be reflected on a
consolidated balance sheet (or the notes thereto) of the Company
and its Subsidiaries, except for liabilities and obligations
(a) reflected or reserved against in the Company’s
consolidated balance sheet as of June 30, 2009 (or the notes
thereto) included in the Company SEC Documents, (b) incurred
in the ordinary course of business since June 30, 2009,
(c) which have been discharged or paid in full prior to the
date of this Agreement, (d) incurred pursuant to or in
connection with the transactions contemplated by this Agreement or
(e) that individually or in the aggregate do not have, and
would not reasonably be expected to have, a Material Adverse
Effect.
20
Section 4.7
Certain Information .
(a) None of
the documents required to be filed by the Company with the SEC or
required to be distributed or otherwise disseminated to the
Company’s stockholders by the Company in connection with the
transactions contemplated by this Agreement (the “ Company
Disclosure Documents ”), including the
Schedule 14D-9, the proxy or information statement of the
Company (the “ Proxy Statement ”), if any, to be
filed with the SEC for use in connection with the solicitation of
proxies from the Company’s stockholders in connection with
the Merger and the Company Stockholders Meeting (as defined in
Section 6.4(b) hereof), if any, will contain any untrue
statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which
they are made, not misleading (i) in the case of the Proxy
Statement, as supplemented or amended, if applicable, at the time
such Proxy Statement or any amendment or supplement thereto is
first mailed to stockholders of the Company and at the time such
stockholders vote on adoption and approval of this Agreement, and
(ii) in the case of any Company Disclosure Document other than
the Proxy Statement, at the time of the filing of such Company
Disclosure Document or any supplement or amendment thereto and at
the time of any distribution or dissemination thereof and at the
Acceptance Time. The Company Disclosure Documents will comply in
all material respects with the requirements of the Exchange Act and
the rules and regulations promulgated thereunder. Notwithstanding
the foregoing, the Company makes no representation or warranty with
respect to any information supplied by Parent or Merger Sub or any
of their respective Representatives for inclusion or incorporation
by reference in the Company Disclosure Documents.
(b) The
information with respect to the Company or any of its Subsidiaries
that the Company furnishes to Parent in writing specifically for
use in the Offer Documents, at the time of the filing of the
Schedule TO, at the time of any distribution or dissemination
of the Offer Documents, and at the Acceptance Time, will not
contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in
order to make the statements made therein, in the light of the
circumstances under which they were made, not
misleading.
Section 4.8
Absence of Certain Changes or Events . Since June 30,
2009, except as otherwise required by this Agreement, and except as
set forth in Section 4.8 of the Company Disclosure Letter,
(i) the businesses of the Company and its Subsidiaries have
been conducted in the ordinary course of business consistent with
past practice, and (ii) there has not been any event,
development, change or state of circumstances that individually or
in the aggregate had, or would reasonably be expected to have, a
Material Adverse Effect.
Section 4.9
Litigation . Except as set forth in Section 4.9 of the
Company Disclosure Letter, (a) there is no material suit,
claim, action, proceeding, arbitration, mediation, conciliation,
consent decree, audit, or investigation (each, an “
Action ”) pending or, to the knowledge of the Company,
threatened against the Company or any of its Subsidiaries or any of
their respective properties, (b) neither the Company nor any
of its Subsidiaries nor any of their respective properties is or
are subject to any material judgment, order, injunction, ruling or
decree of any Governmental Entity, and (c) to the knowledge of
the Company, there is no Action pending or
21
threatened
against any officer or director of the Company that is reasonably
likely to result in any material liability on the part of any
Acquired Company, whether or not such liability is
insured.
Section 4.10
Compliance with Laws .
(a) Except
with respect to SEC Documents (as defined in
Section 4.5(a) hereof), ERISA (as defined in
Section 4.11(a) hereof), Environmental Laws (as defined
in Section 4.13(c)(i) hereof) and Taxes, which are the
subject of Sections 4.5 , 4.11 , 4.13 and
4.14 , respectively, and except as set forth in
Section 4.10(a) of the Company Disclosure Letter, the Company
and each of its Subsidiaries are in, and at all times since
January 1, 2006 have been in, compliance with all Laws
applicable to them or by which any of their respective properties
are bound, except where any non-compliance individually or in the
aggregate does not have, and would not reasonably be expected to
have, a Material Adverse Effect.
(b) Except
as set forth in Section 4.10(b) of the Company Disclosure
Letter, and except with respect to Environmental Laws (which are
the subject of Section 4.13 ), the Company and its
Subsidiaries have in effect all permits, licenses, grants,
easements, clearances, variances, exceptions, consents,
certificates, exemptions, registrations, authorizations,
franchises, orders and approvals of all Governmental Entities
(collectively, “ Permits ”) necessary for them
to own, lease, operate or use their properties and to carry on
their businesses as now conducted, except for any Permits the
absence of which individually or in the aggregate does not have,
and would not reasonably be expected to have, a Material Adverse
Effect. Except as set forth in Section 4.10(b) of the Company
Disclosure Letter, all Permits of the Company and its Subsidiaries
are in full force and effect, except where the failure to be in
full force and effect individually or in the aggregate does not
have, and would not reasonably be expected to have, a Material
Adverse Effect.
(c) Except
as set forth in Section 4.10(c) of the Company Disclosure
Letter, since January 1, 2006, none of the Acquired Companies
has received any written notice or other written communication (or,
to the knowledge of the Company, any oral communication) from any
Governmental Entity regarding any actual or threatened revocation,
withdrawal, suspension, cancellation, termination, deficiency,
dispute or modification with respect to any material
Permit.
(d) Except
as set forth in Section 4.10(d) of the Company Disclosure
Letter, all products developed, manufactured, tested, distributed
or marketed by the Company and its Subsidiaries that are subject to
the jurisdiction of the United States Food and Drug Administration
(the “ FDA ”) or any other medical product
regulatory authority have been and are being developed, tested,
manufactured, distributed and marketed by the Company or its
Subsidiaries, as applicable, in compliance with applicable
regulatory requirements in all material respects, including
pre-market notification, good manufacturing practices, labeling,
advertising, record-keeping, installation, service and adverse
event reporting, and have been and are being tested, investigated,
distributed, marketed, and sold by the Company or its Subsidiaries,
as applicable, in compliance with regulatory requirements in all
material respects. Except as set forth in Section 4.10(d) of the
Company Disclosure Letter, the products of the Company and its
Subsidiaries, where required, have been and are being marketed by
the Company or its Subsidiaries, as applicable, under valid 510(k)
clearances or pre-market approval applications, and, to the
knowledge of the Company, neither the FDA nor any other medical
product
22
regulatory
authority is limiting, suspending or revoking any such clearances
or approvals or changing the marketing classification or labeling
of any such products. There has been no material false or
misleading information or material omission in any product
application, product-related submission or report made by the
Company or its Subsidiaries, as applicable, to or with the FDA.
Except as set forth in Section 4.10(d) of the Company
Disclosure Letter, the Company and its Subsidiaries are in
compliance in all material respects with all legal and regulatory
requirements applicable to the sponsorship or conduct of clinical
trials, including the clinical trial reporting and disclosure
requirements of 42 U.S.C. § 282(j).
(e) To
the knowledge of the Company, and except as set forth in
Section 4.10(e) of the Company Disclosure Letter,
(i) there are no facts that furnish any reasonable basis for
any materially adverse (A) Form FDA-483 inspectional
observations, (B) warning or untitled letters from the FDA,
(C) Section 305 notices or (D) other similar
communications from the FDA or any other applicable medical product
regulatory authority, and (ii) there have been no warning or
untitled letters or similar enforcement communications by the FDA
to the Company relating to the products of the Company since
January 1, 2006. Except as set forth in Section 4.10(e)
of the Company Disclosure Letter, the Company’s products have
not been recalled, withdrawn, subject to correction or removal or
injunction, seized, or suspended (whether voluntarily or otherwise)
since January 1, 2006.
(f) The
Company and its Subsidiaries do not bill any commercial insurance
plan or any health care program administered or funded, in whole or
in part, by the government of the United States, including
Medicare, Medicaid, and TRICARE programs (described in Title XVIII
of the United States Social Security Act (the “ SSA
”), Title XIX of the SSA, and Title 10, Chapter 55 of
the U.S.C., respectively (collectively, “ Federal Health
Care Programs ”) for any item or service. Neither the
Company nor any of its Subsidiaries, nor any officer, director,
managing employee or agent (as those terms are defined in 42 C.F.R.
§ 1001.1001) of the Company or its Subsidiaries has, at any
time been excluded from participation in a Federal Health Care
Program or, to the knowledge of the Company, engaged in any
activity that is in violation of the federal Medicare or federal or
state Medicaid statutes, §§ 1128, 1128A, 1128B, 1128C, or
1877 of the SSA (42 U.S.C. §§ 1320a-7, 1320a-7a,
1320a-7b, 1320a-7c, and 1395nn), the federal TRICARE statute (10
U.S.C. § 1071 et seq.), the civil False Claims Act (31 U.S.C.
§ 3729 et seq.), criminal false claims statutes (e.g., 18
U.S.C. §§ 287 and 1001), the Program Fraud Civil Remedies
Act of 1986 (31 U.S.C. § 3801 et seq.), the anti-fraud and
related provisions of the Health Insurance Portability and
Accountability Act of 1996 (e.g., 18 U.S.C. §§ 1035 and
1347) or similar foreign, federal or state Laws. Except as set
forth in Section 4.10(f) of the Company Disclosure Letter, to
the knowledge of the Company, the Company and its Subsidiaries are
not currently, nor have they been in the past, under investigation
by the Department of Justice (the “ DOJ ”), the
Office of the Inspector General of the U.S. Department of Health
and Human Services, the Centers for Medicare and Medicaid Services,
any state Attorney General, state Medicaid Agency or the FDA for
promotional or other fraud and abuse or related issues. No Person
has filed or, to the knowledge of the Company, has threatened to
file against the Company or any of its Subsidiaries a claim or
action relating to any of the Company’s or its
Subsidiaries’ respective assets or businesses under any
foreign, federal or state whistleblower statute, including under
the False Claims Act (31 U.S.C. § 3729 et seq.).
23
(g) To
the knowledge of the Company, the Company and its Subsidiaries have
at all times complied in a timely manner in all material respects
with the Foreign Corrupt Practices Act of 1977 (15 U.S.C.
§§ 78dd-1 et seq.) and any other applicable Laws
regarding the use of funds for political activity or commercial
bribery. To the knowledge of the Company, there are no
situations with respect to the business of the Company or any of
its Subsidiaries which involved or involves (i) the use of any
corporate funds for unlawful contributions, gifts, entertainment or
other unlawful expenses related to political activity;
(ii) the making of any direct or indirect unlawful payments to
government officials or others from corporate funds or the
establishment or maintenance of any unlawful or unrecorded funds;
or (iii) the receipt of any illegal discounts, rebates or
kick-backs in violation of Law.
Section 4.11
Benefit Plans.
(a) Section 4.11(a)
of the Company Disclosure Letter sets forth a complete and accurate
list of each Company Plan. For purposes of this Agreement,
“Company Plan” means any “employee benefit
plan” (within the meaning of Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended
(“ ERISA ”)), including any “multiemployer
plan” (within the meaning of ERISA Section 3(37)), and
any stock purchase, stock option, severance, change-in-control,
fringe benefit (if material), bonus, incentive, deferred
compensation, employment or other material employee benefit plan,
agreement, program, policy or other arrangement, whether or not
subject to ERISA (including any funding mechanism therefor now in
effect or required in the future as a result of the transactions
contemplated by this Agreement or otherwise), whether formal or
informal, written, legally binding or not, under which any current
or former employee, director or independent contractor of the
Company or its Subsidiaries has any present or future right to
benefits or the Company or its Subsidiaries has had or has any
current or future liability for benefits to or on behalf of any
current or former employee director or independent contractor of
the Company or its Subsidiaries (including an obligation to make
contributions). With respect to each Company Plan, the Company has
furnished or made available to Parent a current, accurate and
complete copy thereof and, to the extent applicable: (i) all
related trust agreements or other funding instruments,
(ii) the most recent determination letter of the U.S. Internal
Revenue Service (the “ IRS ”), if applicable,
(iii) the current summary plan description and other
equivalent written communications by the Company or its
Subsidiaries to their respective employees concerning the extent of
the benefits provided under a Company Plan, (iv) audited
financial reports a
|